PBS should fund drug to treat breast cancer, endometriosis and gender dysphoria, experts recommend

Landmark PBS Recommendation Would Fund Puberty Blockers for Transgender Children and Rescue Cancer Treatments

Wanderstayfinder.com – A recommendation from Australia’s Pharmaceutical Benefits Scheme advisory committee has opened a door that, until now, remained firmly shut for transgender children seeking puberty-blocking medication through the public system. In a single decision, the committee also flagged an urgent gap in breast cancer and endometriosis care created by a pharmaceutical company’s decision to pull a key drug from the market. The combined effect, if adopted by the federal government, would reshape access to hormone-suppressing therapy across several states and territories.

The Urgency Behind the Decision

The committee convened in July on short notice after AstraZeneca announced it would withdraw Zoladex from Australian shelves. That move threatened to leave more than 7,500 women with breast cancer without a viable alternative for oestrogen suppression — a component that oncologists consider essential in certain treatment pathways and fertility-preservation protocols. Both Zoladex and the proposed replacement, triptorelin, suppress the release of oestrogen and testosterone. The World Health Organization classifies them as essential medicines.

Triptorelin has carried a PBS listing since 2006, but only for prostate cancer. The committee’s recommendation is to strip that restriction entirely, funding the drug for every approved and off-label use: breast cancer, endometriosis, precocious puberty, and gender-affirming care. Historically, the government has implemented the committee’s advice, making adoption of this recommendation the expected course of action.

What It Means for Cancer and Endometriosis Patients

Vicki Durston, director of policy and advocacy at Breast Cancer Network Australia, called the recommendation

“a significant step forward”

and warned that for some patients, guaranteed access to the medication could determine whether they survive their treatment course. She noted that uncertainty over supply had already prompted some women to elect oophorectomy — removal of the ovaries — as a precaution against running out of their prescribed therapy.

Marilla Druitt, Victorian state chair of the Royal Australian and New Zealand College of Obstetricians and Gynaecologists, acknowledged that clinical equivalence between triptorelin and Zoladex has not yet been fully established. Still, she viewed the decision as broadly positive for women managing endometriosis and chronic pelvic pain.

“I’m glad we’ve got an alternative,” she said. “That’s fantastic, and it remains to be seen whether or not it will be as good, but pain is so complex, pain is a really hard thing to study because it’s got so many contributors.”

Druitt stressed that post-introduction research would be necessary to confirm therapeutic parity.

A First for Gender-Affirming Care Under the PBS

The most politically charged dimension of the recommendation concerns transgender children. If the federal government accepts the committee’s advice, puberty-blocking medication would be funded through the PBS for gender-affirming purposes for the first time. That shift would eliminate a significant financial barrier in Queensland and the Northern Territory, where such treatment has not been available free of charge through public hospitals.

In other states and territories, the care was already provided at no cost via the public system. Queensland, however, moved last January to prohibit its public hospitals from prescribing gender-affirming medications to transgender children. At the time of the ban, more than 491 patients were on the waitlist at the state’s gender clinic. The state supreme court struck down the prohibition, but the government immediately reimposed it. The Northern Territory followed with a comparable restriction.

Stuart Aitken, medical director of Gender Health Australia, described the committee’s move as generating

“absolute joy”

among his patients.

“It takes away a huge barrier to accessing evidence-based care,” he said. “It means that the ban has a very limited effect.”

Cost, Access, and the Question of Off-Label Use

Fiona Bisshop, a Brisbane general practitioner at Stonewall Medical Centre, put the financial stakes in concrete terms. Without a PBS listing, private prescribing of a puberty blocker runs roughly $3,000 per year. With the listing, that figure drops to about $300 annually — roughly $25 a week.

“It kind of makes [the ban] a joke, really … it makes it laughable that the PBS is saying you can prescribe this for anything,” she said.

Bisshop identified cost as one of the principal obstacles preventing Queensland families from accessing treatment. The state government’s own review of puberty-blocking and hormone therapies reached a parallel conclusion, flagging legal, ethical, governance, regulatory, and oversight risks created by the ban, including

“inequity because of socioeconomic status or geographical location.”

The review cited low-quality but consistent evidence indicating that, when carefully prescribed, puberty blockers can reduce gender-related distress that might otherwise intensify during adolescence. It did not recommend maintaining the prohibition.

Nevertheless, Queensland health minister Tim Nicholls extended the ban to at least 2031, tying its continuation to the outcome of a trial currently underway in the United Kingdom.

Like most agents used in gender-affirming protocols, triptorelin is prescribed off label for this purpose and does not carry Therapeutic Goods Administration approval for that specific indication. Should the expanded PBS coverage be approved, it would take effect in November.

Broader Implications

The recommendation sits at the intersection of pharmaceutical supply-chain risk, public-health funding policy, and an ongoing political dispute over transgender healthcare. By linking the cancer-treatment emergency to the gender-affirming care question in a single committee action, the advisory body has made it difficult for the government to address one issue without confronting the other. For the thousands of women awaiting breast-cancer therapy and the transgender children on clinic waitlists, the November deadline now carries weight well beyond routine PBS administration.